Why the study?
Pro-inflammatory pathways are important in follow-ups of patients with ICDs for HFrEF, and the prognostic value of the systemic immune-inflammation index needed evaluation for long-term mortality and appropriate ICD therapy.
Does a higher systemic immune-inflammation index predict long-term mortality and appropriate ICD therapy in patients with HFrEF and an ICD?
Population
1011 patients with ICD for HFrEF
Comparison
Higher SII (≥1119) vs lower SII based on optimal cut-off value
Design
Retrospective study
Follow-up
10-year
Loading...
SII may aid prognostication in HFrEF patients with ICDs; leaves open prospective validation before clinical use.
Does a higher systemic immune-inflammation index predict long-term mortality and appropriate ICD therapy in patients with HFrEF and an ICD?
A higher systemic immune-inflammation index (≥1119) is an independent predictor of long-term mortality and appropriate ICD therapy in patients with HFrEF.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: